TAZ and YAP are frequently activated oncoproteins in sarcomas.
about
YAP promotes tumorigenesis and cisplatin resistance in neuroblastomaPrognostic value of the Hippo pathway transcriptional coactivators YAP/TAZ and β1-integrin in conventional osteosarcoma.Overexpression of FZD7 promotes glioma cell proliferation by upregulating TAZ.YAP and the Hippo pathway in pediatric cancer.USP21 regulates Hippo pathway activity by mediating MARK protein turnover.The Transcriptional Coactivator TAZ Is a Potent Mediator of Alveolar Rhabdomyosarcoma Tumorigenesis.Potential Value of YAP Staining in Rhabdomyosarcoma.Epithelioid Hemangioendothelioma as a Model of YAP/TAZ-Driven Cancer: Insights from a Rare Fusion SarcomaSoft Tissue Sarcoma Cancer Stem Cells: An OverviewA comprehensive evaluation of Hippo pathway silencing in sarcomas
P2860
Q33913845-E2B49312-BEC3-43B3-944E-D1EB6F4E797CQ37662115-09487714-AA36-4BD5-9421-A2F054C82B01Q37699166-234066AD-B092-46DE-AAA0-8B0E7AA28BE8Q39374990-C6B16A4B-37D9-4D9C-A031-7E69522268A0Q42080281-DFAC8340-E56D-49C3-8C83-C719AE0438C4Q52668719-47EBACCA-DFBF-41D6-8F7A-58F4B05E3A57Q52723273-D9DDCC7B-46B5-4430-8C85-99D9F019428AQ57646291-CB259F7A-64AF-46FF-8648-D223C4176AFDQ58707604-F19F89BA-115C-4A2A-9F5E-6C7F1F82DC8BQ58801087-78B73D8A-2EF8-49E0-BD57-860EEFE17A5F
P2860
TAZ and YAP are frequently activated oncoproteins in sarcomas.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
TAZ and YAP are frequently activated oncoproteins in sarcomas.
@en
type
label
TAZ and YAP are frequently activated oncoproteins in sarcomas.
@en
prefLabel
TAZ and YAP are frequently activated oncoproteins in sarcomas.
@en
P2093
P2860
P356
P1433
P1476
TAZ and YAP are frequently activated oncoproteins in sarcomas
@en
P2093
Allyn M Lambertz
Benjamin J Miller
Brittany L Pakalniskis
Christopher S Stipp
Colleen A Fullenkamp
Erica C Savage
Georgina K Ofori-Amanfo
Johanna M Savage
Omar I Jaber
Sarah L Hall
P2860
P304
30094-30108
P356
10.18632/ONCOTARGET.8979
P407
P577
2016-05-01T00:00:00Z